- USP29 alleviates the progression of MASLD by stabilizing ACSL5 through K48 deubiquitination
-
Hu S, Wang Z, Zhu K, Shi H, Qin F, Zhang T, tian S, Ji Y, Zhang J, Qin J, She Z, Zhang X, Zhang P, Li H
- KMID: 2563417
- Clin Mol Hepatol.
- 2025 Jan;31(1):147-165.
- doi: 10.3350/cmh.2024.0478
Background/Aims: Metabolic dysfunction–associated steatotic liver disease (MASLD) is a chronic liver disease characterized by hepatic steatosis. Ubiquitin-specific protease 29 (USP29) plays pivotal roles in hepatic ischemiareperfusion injury and hepatocellular carcinoma,... -
- CITED
-
- Close
- SHARE
-
- Close
